University of Kansas Medical Center

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

University of Kansas Medical Center
Mar 16, 2025, 11:25 | Blog
Al-Ola A Abdallah: Daratumumab-Based Quadruplet vs. Triplet Induction Regimens in Transplant-Eligible NDMM
Al-Ola A Abdallah, Associate Professor and Plasma Cell disorder program Director at University of Kansas…
Mar 3, 2025, 12:59 | Blog
Al-Ola A Abdallah: Chemotherapy-Induced Peripheral Neuropathy Hematological Patients
Al-Ola A Abdallah, Associate Professor and Plasma Cell disorder program Director at University of Kansas…
Feb 9, 2025, 15:37 | Science
Al-Ola A Abdallah: Clinicopathologic Predictors of Renal Response and Survival in NDMM with Renal Impairment
Al-Ola A Abdallah, Associate Professor and Plasma Cell disorder program Director at University of Kansas…
Jan 28, 2025, 06:26 | Blog
Muhammad Umair Mushtaq: University of Kansas Medical Center Insights
Muhammad Umair Mushtaq, Associate Professor of Medicine at the University of Kansas Medical Center, shared…
Nov 25, 2024, 18:11 | Insight
Al-Ola A Abdallah: Early Safety and Efficacy of CAR-T Cell Therapy in Precursor Myeloma
Al-Ola A Abdallah, Plasma Cell Disorder Program Director, Division of HMCT/University of Kansas Medical Center,…
Oct 26, 2024, 12:33 | Insight
Al-Ola A Abdallah: Will we soon see Belantamab back in relapse myeloma as part of a combination therapy?
Al-Ola A Abdallah, Associate Professor, Plasma Cell disorder program Director, Division of HMCT at University…
Aug 24, 2024, 10:20 | Blog
Al-Ola Abdallah: Introduction to U.S. Myeloma Innovations Research Collaborative Group
Al-Ola Abdallah, Associate Professor Of Medicine at the University of Kansas Medical Center, shared a…
Jul 25, 2024, 20:13 | Insight
Optimizing the Post-CAR T Monitoring Period
Al-Ola A Abdallah, Associate Professor and Plasma Cell Disorder Program Director at Division of HMCT/University…
Jun 10, 2024, 12:49 | Dialogues
ASCO24 Updates: New Hope for Advanced Melanoma Patients: TIL Therapy Explained
The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the largest and most…
All: 9 Posts: 1 - 100
Special Coverage